Ketorolac 10 mg tabs — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Acute Musculoskeletal Pain

• Ibuprofen
• Naproxen
• Tramadol

About Ketorolac 10 mg tabs

Ketorolac 10 mg is a powerful nonsteroidal anti-inflammatory drug (NSAID) prescribed for the short-term management of moderately severe acute pain. If you're seeking effective relief without the high costs, TheDrugClub has you covered. ### What Ketorolac 10 mg Treats

Ketorolac 10 mg tablets are primarily used for the short-term (typically up to five days) management of moderately severe acute pain that requires analgesia at the opioid level. This often includes pain experienced after surgical procedures, dental work, or other acute injuries where strong, non-narcotic pain relief is necessary. It's a go-to option when immediate and effective pain control is crucial, helping patients recover more comfortably without the concerns associated with long-term opioid use. It is not intended for chronic pain conditions due to potential side effects with prolonged use. ### How Ketorolac 10 mg Works

As a potent nonsteroidal anti-inflammatory drug (NSAID), ketorolac works by inhibiting the body's production of prostaglandins. Prostaglandins are naturally occurring lipid compounds that play a vital role in mediating pain, inflammation, and fever. By blocking the enzymes (COX-1 and COX-2) responsible for prostaglandin synthesis, ketorolac effectively reduces these symptoms at the site of injury or inflammation. This mechanism of action allows it to provide significant pain relief and reduce swelling, making it a highly effective treatment for acute pain episodes. ### Typical Costs of Ketorolac 10 mg

The cost of ketorolac 10 mg can vary significantly depending on your

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ketorolac 10 mg tabs is approved for (FDA label)

Carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. Acute Pain in Adult Patients Ketorolac tromethamine tablets are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary.

Source: Read the full FDA label on DailyMed. Label effective date: August 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ketorolac 10 mg tabs (FDA label)

WARNING Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary. The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days. Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including ketorolac tromethamine tablets can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS ). CARDIOVASCULAR THOMBOTIC EVENTS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

Source: FDA prescribing information (DailyMed). Set ID: 04d5114e-332b-4ed0-85df-b276c1dc296c. SPL document ID: 5a1bcc43-0f0c-fb95-e063-6394a90af8cc. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ketorolac 10 mg tabs (FDA label)

Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as GI ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions and liver failure (see Boxed WARNING , WARNINGS , PRECAUTIONS , and DOSAGE AND ADMINISTRATION ). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately.

Source: FDA prescribing information (DailyMed). Set ID: 04d5114e-332b-4ed0-85df-b276c1dc296c. SPL document ID: 5a1bcc43-0f0c-fb95-e063-6394a90af8cc. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ketorolac 10 mg tabs (FDA label)

(See also Boxed WARNING ). Ketorolac tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine. Ketorolac tromethamine is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Ketorolac tromethamine should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS , Anaphylactoid Reactions , and PRECAUTIONS , Preexisting Asthma ). Ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery. Ketorolac tromethamine is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: 04d5114e-332b-4ed0-85df-b276c1dc296c. SPL document ID: 5a1bcc43-0f0c-fb95-e063-6394a90af8cc. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ketorolac 10 mg tabs (FDA label)

WARNINGS (See also Boxed WARNING ). The total combined duration of use of ketorolac tromethamine tablets and intravenous or intramuscular dosing of ketorolac tromethamine is not to exceed 5 days in adults. Ketorolac tromethamine tablets are not indicated for use in pediatric patients. The most serious risks associated with ketorolac tromethamine are: Gastrointestinal Effects – Risk of Ulceration, Bleeding, and Perforation Ketorolac tromethamine is contraindicated in patients with previously documented peptic ulcers and/or GI bleeding. Ketorolac tromethamine can cause serious gastrointestinal (GI) adverse events including bleeding, ulceration and perforation, of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with ketorolac tromethamine. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic.

Source: FDA prescribing information (DailyMed). Set ID: 04d5114e-332b-4ed0-85df-b276c1dc296c. SPL document ID: 5a1bcc43-0f0c-fb95-e063-6394a90af8cc. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ketorolac 10 mg tabs (FDA label)

Ketorolac is highly bound to human plasma protein (mean 99.2%). There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs. Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 mcg/mL to 10 mcg/mL. Ketorolac does not alter digoxin protein binding. In vitro studies indicate that, at therapeutic concentrations of salicylate (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels. Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac tromethamine protein binding.

Source: FDA prescribing information (DailyMed). Set ID: 04d5114e-332b-4ed0-85df-b276c1dc296c. SPL document ID: 5a1bcc43-0f0c-fb95-e063-6394a90af8cc. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.